Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: TrialsWest
Location: 6 Barrington Street, Spearwood, WA, 6163
Lead Doctor: Professor Peter Bremner
IRB Committee: This study has been reviewed and approved by the Bellberry Human Research Ethics Committee

Background

Meningococcal disease is rare but can be deadly. It may cause infections in the lining of the brain, spinal cord and bloodstream. Doctors treat meningococcal disease with antibiotics. However, being vaccinated can help protect against meningococcal disease. 

A vaccine works by helping your body prepare to fight off infections when you come into contact with it. The purpose of this study is to obtain human serum from blood samples collected from healthy adults, before and after being administered a meningococcal vaccination. These samples will be used for developing and checking the quality of the blood tests that are used to measure the effect of vaccines.

This study is looking for healthy adults aged 18 to 50 years old who have not yet had a meningococcal vaccine or meningococcal disease. Eligible participants must be at least  50 kg in weight and have a BMI less than 32. Participants must attend 4 or 5 study site visits over a period of 6 to 8 months and will be compensated for their time and travel.

Why Participate? 

• You will receive a meningococcal vaccine that is already registered and used in Australia at no cost.
• The vaccination you receive may help protect you from getting meningococcal disease.
• You will be compensated for participating in this study.
• You will be helping to advance medical research.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Healthy adults aged 18 to 50 years old who have not previously received a meningococcal vaccine or have not yet had meningococcal disease.
• Must weigh at least 50 kg and have a BMI less than 32.
• Able to attend 4 or 5 study visits at the research site over a period of approximately 6 to 8 months. Each study visit will last 1-2 hours.